444 related articles for article (PubMed ID: 23335275)
1. Age-related treatment patterns in sickle cell disease patients and the associated sickle cell complications and healthcare costs.
Blinder MA; Vekeman F; Sasane M; Trahey A; Paley C; Duh MS
Pediatr Blood Cancer; 2013 May; 60(5):828-35. PubMed ID: 23335275
[TBL] [Abstract][Full Text] [Related]
2. Persistence and compliance of deferoxamine versus deferasirox in Medicaid patients with sickle-cell disease.
Jordan LB; Vekeman F; Sengupta A; Corral M; Guo A; Duh MS
J Clin Pharm Ther; 2012 Apr; 37(2):173-81. PubMed ID: 21592159
[TBL] [Abstract][Full Text] [Related]
3. Long-term persistency and costs associated with the use of iron chelation therapies in the treatment of Sickle cell disease within Medicaid programs.
Armstrong EP; Skrepnek GH; Sasane M; Snodgrass SM; Ballas SK
J Med Econ; 2013; 16(1):10-8. PubMed ID: 22947171
[TBL] [Abstract][Full Text] [Related]
4. Adherence to iron chelation therapy and associated healthcare resource utilization and costs in Medicaid patients with sickle cell disease and thalassemia.
Vekeman F; Sasane M; Cheng WY; Ramanakumar AV; Fortier J; Qiu Y; Duh MS; Paley C; Adams-Graves P
J Med Econ; 2016; 19(3):292-303. PubMed ID: 26618853
[TBL] [Abstract][Full Text] [Related]
5. Outcomes, utilization, and costs among thalassemia and sickle cell disease patients receiving deferoxamine therapy in the United States.
Delea TE; Hagiwara M; Thomas SK; Baladi JF; Phatak PD; Coates TD
Am J Hematol; 2008 Apr; 83(4):263-70. PubMed ID: 17924547
[TBL] [Abstract][Full Text] [Related]
6. Age-Related Emergency Department Reliance in Patients with Sickle Cell Disease.
Blinder MA; Duh MS; Sasane M; Trahey A; Paley C; Vekeman F
J Emerg Med; 2015 Oct; 49(4):513-522.e1. PubMed ID: 25910824
[TBL] [Abstract][Full Text] [Related]
7. Hydroxyurea adherence and associated outcomes among Medicaid enrollees with sickle cell disease.
Candrilli SD; O'Brien SH; Ware RE; Nahata MC; Seiber EE; Balkrishnan R
Am J Hematol; 2011 Mar; 86(3):273-7. PubMed ID: 21328441
[TBL] [Abstract][Full Text] [Related]
8. The cost of health care for children and adults with sickle cell disease.
Kauf TL; Coates TD; Huazhi L; Mody-Patel N; Hartzema AG
Am J Hematol; 2009 Jun; 84(6):323-7. PubMed ID: 19358302
[TBL] [Abstract][Full Text] [Related]
9. Multicenter COMPACT study of COMplications in patients with sickle cell disease and utilization of iron chelation therapy.
Jordan L; Adams-Graves P; Kanter-Washko J; Oneal PA; Sasane M; Vekeman F; Bieri C; Magestro M; Marcellari A; Duh MS
Curr Med Res Opin; 2015 Mar; 31(3):513-23. PubMed ID: 25495135
[TBL] [Abstract][Full Text] [Related]
10. Clinical and economic burden of infused iron chelation therapy in the United States.
Payne KA; Desrosiers MP; Caro JJ; Baladi JF; Lordan N; Proskorovsky I; Ishak K; Rofail D
Transfusion; 2007 Oct; 47(10):1820-9. PubMed ID: 17880607
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of hydroxyurea in reducing the frequency of pain episodes and hospitalization in pediatric sickle cell disease.
Stallworth JR; Jerrell JM; Tripathi A
Am J Hematol; 2010 Oct; 85(10):795-7. PubMed ID: 20645429
[TBL] [Abstract][Full Text] [Related]
12. Serum angiogenin level in sickle cell disease and beta thalassemia patients.
Matter RM; Abdelmaksoud AA; Shams MA; Bebawy EK
Pediatr Hematol Oncol; 2014 Feb; 31(1):50-6. PubMed ID: 24483841
[TBL] [Abstract][Full Text] [Related]
13. Non-transferrin-bound labile plasma iron and iron overload in sickle-cell disease: a comparative study between sickle-cell disease and beta-thalassemic patients.
Koren A; Fink D; Admoni O; Tennenbaum-Rakover Y; Levin C
Eur J Haematol; 2010 Jan; 84(1):72-8. PubMed ID: 19732137
[TBL] [Abstract][Full Text] [Related]
14. Chelation treatment in sickle-cell-anaemia: much ado about nothing?
Lucania G; Vitrano A; Filosa A; Maggio A
Br J Haematol; 2011 Sep; 154(5):545-55. PubMed ID: 21707578
[TBL] [Abstract][Full Text] [Related]
15. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members.
Yawn BP; Buchanan GR; Afenyi-Annan AN; Ballas SK; Hassell KL; James AH; Jordan L; Lanzkron SM; Lottenberg R; Savage WJ; Tanabe PJ; Ware RE; Murad MH; Goldsmith JC; Ortiz E; Fulwood R; Horton A; John-Sowah J
JAMA; 2014 Sep; 312(10):1033-48. PubMed ID: 25203083
[TBL] [Abstract][Full Text] [Related]
16. Improved survival in red blood cell transfusion dependent patients with primary myelofibrosis (PMF) receiving iron chelation therapy.
Leitch HA; Chase JM; Goodman TA; Ezzat H; Rollins MD; Wong DH; Badawi M; Leger CS; Ramadan KM; Barnett MJ; Foltz LM; Vickars LM
Hematol Oncol; 2010 Mar; 28(1):40-8. PubMed ID: 19557769
[TBL] [Abstract][Full Text] [Related]
17. The Economic Burden of End-Organ Damage Among Medicaid Patients with Sickle Cell Disease in the United States: A Population-Based Longitudinal Claims Study.
Campbell A; Cong Z; Agodoa I; Song X; Martinez DJ; Black D; Lew CR; Varker H; Chan C; Lanzkron S
J Manag Care Spec Pharm; 2020 Sep; 26(9):1121-1129. PubMed ID: 32597290
[TBL] [Abstract][Full Text] [Related]
18. Medical complications, resource utilization and costs in patients with myelofibrosis by frequency of blood transfusion and iron chelation therapy.
Vekeman F; Cheng WY; Sasane M; Huynh L; Duh MS; Paley C; Mesa RA
Leuk Lymphoma; 2015; 56(10):2803-11. PubMed ID: 25676036
[TBL] [Abstract][Full Text] [Related]
19. The association between hydroxyurea adherence and opioid utilization among Texas Medicaid enrollees with sickle cell disease.
Kang HA; Barner JC
J Manag Care Spec Pharm; 2020 Nov; 26(11):1412-1422. PubMed ID: 33119448
[No Abstract] [Full Text] [Related]
20. Trends in blood transfusion, hydroxyurea use, and iron overload among children with sickle cell disease enrolled in Medicaid, 2004-2019.
Tang AY; Zhou M; Maillis AN; Lai KW; Lane PA; Snyder AB
Pediatr Blood Cancer; 2023 Mar; 70(3):e30152. PubMed ID: 36579749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
